This report provides key trends in the medical device industry for this week (April 27 - May 2, 2026). From the perspective of a regulatory consultant specializing in the gastrointestinal endoscopy field, we will discuss notable topics that significantly impact the industry, such as financial results of major manufacturers, M&A activities, cybersecurity challenges, and the latest regulatory developments.
1. Company Trends and Performance: Intuitive Surgical's Strong Earnings and Stryker's Cyberattack Impact
News Highlights
Intuitive Surgical, known for its "da Vinci" surgical robot, announced its Q1 2026 financial results, reporting sales of $2.77 billion, a 23% increase year-over-year 1: Intuitive — Q1 2026 results. The number of da Vinci systems installed reached 431, with global growth driven by an increase in surgical procedures.
Stryker reported Q1 2026 sales of $6.02 billion, up 2.6% year over year, and adjusted EPS of $2.60, down 8.5%. It discussed recovery from the cyber incident first disclosed on March 11 and maintained its full-year organic-sales and adjusted-EPS guidance. Adjusted EPS is distinct from GAAP diluted EPS of $1.93 2: Stryker — Q1 2026 results (SEC filing).
On April 24, Medtronic disclosed unauthorized access to data in certain corporate IT systems. At that date, it had identified no impact on products, patient safety, or manufacturing and distribution operations. It was investigating which personal information may have been accessed and said it would notify and support affected people as needed 3: Medtronic — April 24, 2026 statement (SEC filing).
Impact on the Industry
Intuitive Surgical's performance indicates robust global demand for minimally invasive surgery. In contrast, the cases of Stryker and Medtronic demonstrate the risk that vulnerabilities in medical device manufacturers' supply chains and IT infrastructure can directly affect corporate performance and the supply system in healthcare settings.
Japan added cybersecurity requirements to Article 12(3) of the Essential Principles through the March 9, 2023 amendment, applicable from April 1, 2023. Following a one-year transition, affected medical devices with cybersecurity risk have had to comply from April 1, 2024. Manufacturers should assess the applicable lifecycle controls, including SBOM, vulnerability response and post-market management, against the product’s connectivity and operating environment PMDA: medical-device cybersecurity.
2. M&A and Business Strategy: Strategic Acquisitions by J&J and CareDx
News Highlights
Johnson & Johnson (J&J) announced the acquisition of Atraverse Medical, Inc. (a privately held U.S. medical device startup) to expand its cardiovascular portfolio 4: Johnson & Johnson — Atraverse acquisition agreement. Atraverse has developed the HOTWIRE Transseptal Access System, an FDA-cleared radiofrequency guidewire used for treating conditions such as atrial fibrillation, which has been used in approximately 3,000 cases to date. The system received FDA 510(k) clearance in May 2024 and additional clearance in December 2025 for an integrated RF generator. One of Atraverse's founders is Steven Mickelsen, who was also a founder of Farapulse, which Boston Scientific acquired in 2021. The transaction is expected to close in Q2 2026, and the financial terms were not disclosed.
Additionally, CareDx, a company specializing in diagnostics for transplant medicine, entered into an agreement to acquire Naveris, a developer of minimal residual disease (MRD) surveillance tests for virus-associated cancers, for up to $260 million (an upfront payment of $160 million + up to $100 million in milestones) to make a full-scale entry into the oncology field 5: CareDx — Naveris acquisition agreement. Naveris's flagship product, "NavDx," is a liquid biopsy test for HPV-related cancers, which received Medicare coverage in 2023. Naveris's sales were approximately $34 million in 2025 and $12 million in Q1 2026. The transaction is expected to close in Q3 2026.
Impact on the Industry
J&J's acquisition is part of its strategy to expand its market share in the rapidly growing arrhythmia (ablation) treatment market and will be integrated with its existing platforms, "Varipulse" and "Carto 3 mapping system." Meanwhile, CareDx's acquisition of Naveris demonstrates a diversification of business from its traditional transplant area into Naveris’ "viral-mediated-cancer minimal residual disease (MRD) surveillance" platform market (estimated by CareDx at $4.5 billion). The trend of large companies acquiring innovative startups with strengths in specific disease areas is expected to continue.
3. New Products and Technological Innovation: TaeWoong Medical's SPAXUS Stent Receives FDA 510(k) Clearance
News Highlights
TaeWoong Medical USA announced FDA 510(k) clearance for its lumen-apposing metal stent, Niti-S SPAXUS, for endoscopic drainage. FDA's K252648 decision, dated March 13, 2026, is a substantial-equivalence clearance, not a PMA approval 6: FDA — K252648, Niti-S SPAXUS.
The fully covered, self-expanding stent has a bi-flange design and silicone coating. Its cleared indications differ by diameter (all models are 20 mm long):
- 8 mm: Transgastric or transduodenal drainage of symptomatic pancreatic pseudocysts at least 6 cm in size, adherent to the gastric or bowel wall and free of solid debris
- 10 mm and 16 mm: Drainage of symptomatic pancreatic pseudocysts or walled-off necrosis at least 6 cm in size and adherent to the gastric or bowel wall; also gallbladder drainage in patients with acute cholecystitis who are at high surgical risk
For pancreatic pseudocysts and walled-off necrosis, implantation is limited to 60 days, with removal after resolution is confirmed. Consult the FDA labeling for the full conditions of use.
Impact on the Industry
In a prospective pancreatic-pseudocyst study, 33 of 34 evaluable patients (97.1%) achieved clinical success, defined as a reduction in pseudocyst size of at least 50% at day 30 or day 60 (each ±10 days). No procedure- or device-related serious adverse events were reported during the study follow-up 6: FDA — K252648, Niti-S SPAXUS. These results should be read within that study's population and endpoints.
For Japan, the intended use, generic device name and differences from existing products must be assessed to determine classification and the regulatory pathway. Reimbursement also requires a product-specific assessment against existing functional categories and applicable rules; a Class III classification or C1 submission cannot be assumed from the US clearance alone.
4. Regulatory Trends: Insurance Coverage for Software as a Medical Device (SaMD) and European AI Regulations
News Highlights
In Japan, discussions are active regarding the social implementation of Software as a Medical Device (SaMD). In addition to accelerating the review process for regulatory applications by the Pharmaceuticals and Medical Devices Agency (PMDA), strategic considerations for appropriate pricing and insurance coverage of SaMD in the 2026 (Reiwa 8) medical fee revision are ongoing 7: 厚生労働省 — 令和8年度診療報酬改定.
The EU AI Act distinguishes its general application date from the dates for high-risk AI requirements. For medical-device AI, classification depends on the conditions in Article 6(1), including the relevant Annex I product legislation and whether third-party conformity assessment is required. The relationship with MDR/IVDR and applicable transitional provisions must be assessed for each product.
Impact on the Industry
For software-only medical devices, obtaining "regulatory approval" and "insurance coverage" are two sides of the same coin. The modernization of PMDA reviews and the improvement of the insurance system will boost the growth of the domestic digital health market.
On the other hand, for companies aiming for global expansion, compliance with strict European AI regulations will be a new hurdle. In areas where the EU MDR, EU AI Act, and PMDA Basic Requirements for cybersecurity intersect, a strategy incorporating regulatory requirements from each country is essential from the early stages of product development. In particular, manufacturers dealing with AI endoscopes (which are also being implemented in the gastrointestinal endoscopy field) need to compare the tests and documents required in the countries and regions where they plan to sell, and consider which can be used in common and which must be prepared separately.
5. Key Takeaways for This Week
The week of April 27 to May 2, 2026 highlighted several converging trends that regulatory professionals and device manufacturers should monitor closely:
| Topic | Key Development | Implication |
|---|---|---|
| Japan market access | Product-specific classification and reimbursement planning | Confirm the pathway against intended use and existing categories |
| FDA 510(k) | SPAXUS clearance with diameter-specific indications | Check the full labeling and implantation limits |
| M&A Activity | J&J/Atraverse and CareDx/Naveris agreements | Portfolio expansion in cardiac access and oncology diagnostics |
| SaMD/AI Regulations | Japan fee revision and EU AI Act implementation | Distinguish general and high-risk application dates; see the dated update below |
For companies pursuing simultaneous regulatory submissions in Japan, the US, and Europe, the convergence of PMDA modernization, FDA AI/ML guidance, and EU AI Act requirements creates both challenges and opportunities. Early engagement with regulatory consultants familiar with all three jurisdictions is increasingly important.
Related Articles & Tools
- Japan Medical Device Approval Process: PMDA, Pharmaceutical Affairs Law, MAH/DMAH Basics
- Medical Device Approval Category: New, Improved, and Generic
- QMS Conformity Assessment Preparation Guide
- Japan Medical Device Labeling & IFU Requirements
- Medical Device Regulatory Affairs Consulting
Correction and update — October 17, 2026: The four language versions now distinguish SPAXUS indications by diameter, its 60-day pancreatic implantation limit, study endpoints and 510(k) clearance terminology. Japan classification and reimbursement are described as product-specific assessments. After this article was first published, the AI Omnibus entered into force on July 27, 2026. The main high-risk requirements for product-related systems under Article 6(1) and Annex I apply from August 2, 2028; Annex III requirements apply from December 2, 2027. These dates differ from the general August 2, 2026 application date. This is a subsequent regulatory update; the original reporting period is unchanged. Source restoration also limits the cyber-incident accounts to the contemporary company disclosures, identifies Stryker’s adjusted EPS, and clarifies the scope and application dates of Japan’s cybersecurity requirements.
Sources for the update: European Commission: AI Omnibus enters into force · European Parliament: Regulation (EU) 2026/1744 summary
Correction, October 18, 2026: The affected product names, technical terms, and scope or timing of regulatory and numerical statements have been corrected against source evidence. The original publication date is unchanged.